Neurodiagnoses
A new tridimensional diagnostic framework for CNS diseases
This project is focused on developing a novel nosological and diagnostic framework for CNS diseases by using advanced AI techniques and integrating data from neuroimaging, biomarkers, and biomedical ontologies.
We aim to create a structured, interpretable, and scalable diagnostic tool.
What is this about and what can I find here?
Overview
The Tridimensional Diagnostic Framework redefines CNS diseases can be classified and diagnosed by focusing on:
- Axis 1: Etiology (genetic or other causes of diseases).
 - Axis 2: Molecular Markers (biomarkers).
 - Axis 3: Neuroanatomoclinical correlations (linking clinical symptoms to structural changes in the nervous system).
 
This methodology enables:
- Greater precision in diagnosis.
 - Integration of incomplete datasets using AI-driven probabilistic modeling.
 - Stratification of patients for personalized treatment.
 
The case of neurodegenerative diseases
There have been described these 3 diagnostic axes:

Neurodegenerative diseases can be studied and classified in a tridimensional scheme with three axes: anatomic–clinical, molecular, and etiologic. CSF, cerebrospinal fluid; FDG, fluorodeoxyglucose; MRI, magnetic resonance imaging; PET, positron emission tomography.
Axis 1: Etiology
- Description: Focuses on genetic and sporadic causes, identifying risk factors and potential triggers.
 - Examples: APOE ε4 as a genetic risk factor, or cardiovascular health affecting NDD progression.
 - Tests: Genetic testing, lifestyle, and cardiovascular screening.
 
Axis 2: Molecular Markers
- Description: Analyzes primary (amyloid-beta, tau) and secondary biomarkers (NFL, GFAP) for tracking disease progression.
 - Examples: CSF amyloid-beta concentrations to confirm Alzheimer’s pathology.
 - Tests: Blood/CSF biomarkers, PET imaging (Tau-PET, Amyloid-PET).
 
Axis 3: Neuroanatomoclinical
- Description: Links clinical symptoms to neuroanatomical changes, such as atrophy or functional impairments.
 - Examples: Hippocampal atrophy correlating with memory deficits.
 - Tests: MRI volumetrics, FDG-PET, neuropsychological evaluations.
 
Applications
This system enhances:
- Research: By stratifying patients, reduces cohort heterogeneity in clinical trials.
 - Clinical Practice: Provides dynamic diagnostic annotations with timestamps for longitudinal tracking.
 
Who has access?
We welcome contributions from the global community. Let’s build the future of neurological diagnostics together!
How to Contribute
- Access the `/docs` folder for guidelines.
 - Use `/code` for the latest AI pipelines.
 - Share feedback and ideas in the wiki discussion pages.
 
Key Objectives
- Develop interpretable AI models for diagnosis and progression tracking.
 - Integrate data from Human Phenotype Ontology (HPO), Gene Ontology (GO), and other biomedical resources.
 - Foster collaboration among neuroscientists, AI researchers, and clinicians.
 
Main contents
- `/docs`: Documentation and contribution guidelines.
 - `/code`: Machine learning pipelines and scripts.
 - `/data`: Sample datasets for testing.
 - `/outputs`: Generated models, visualizations, and reports.
 - Methodology
 - Results
 - to-do-list